ArticleCPT: pharmacometrics & systems pharmacology2013
Drug and disease model resources: a consortium to create standards and tools to enhance model-based drug development.
Article in CPT: pharmacometrics & systems pharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Reproducibility in pharmacometrics applied in a phase III trial of BCG-vaccination for COVID-19.Scientific reports · 2023Trial
- Building Hybrid Pharmacometric-Machine Learning Models in Oncology Drug Development: Current State and Recommendations.CPT: pharmacometrics & systems pharmacology · 2026Review
- Bridging academia and industry: advancing systems biology and QSP education through AstraZeneca's collaborative partnerships.Frontiers in systems biology · 2025Review
- Categorizing metadata to help mobilize computable biomedical knowledge.Learning health systems · 2022Article
- Drug Dosing Recommendations for All Patients: A Roadmap for Change.Clinical pharmacology and therapeutics · 2021Review
- Reproducibility of Quantitative Systems Pharmacology Models: Current Challenges and Future Opportunities.CPT: pharmacometrics & systems pharmacology · 2019Review
- A Survey of Software Tool Utilization and Capabilities for Quantitative Systems Pharmacology: What We Have and What We Need.CPT: pharmacometrics & systems pharmacology · 2019Article
- Pharmacokinetic-Pharmacodynamic Modeling in Pediatric Drug Development, and the Importance of Standardized Scaling of Clearance.Clinical pharmacokinetics · 2019Review
- Data standards for model-informed drug development: an ISoP initiative.Journal of pharmacokinetics and pharmacodynamics · 2018Article
- The Standard Output: A Tool-Agnostic Modeling Storage Format.CPT: pharmacometrics & systems pharmacology · 2018Article
- Complex Bayesian Modeling Workflows Encoding and Execution Made Easy With a Novel WinBUGS Plugin of the Drug Disease Model Resources Interoperability Framework.CPT: pharmacometrics & systems pharmacology · 2018Article
- PharmML in Action: an Interoperable Language for Modeling and Simulation.CPT: pharmacometrics & systems pharmacology · 2017Article
- Thoughtflow: Standards and Tools for Provenance Capture and Workflow Definition to Support Model-Informed Drug Discovery and Development.CPT: pharmacometrics & systems pharmacology · 2017Article
- Harnessing Big Data for Systems Pharmacology.Annual review of pharmacology and toxicology · 2017Review
- ProbOnto: ontology and knowledge base of probability distributions.Bioinformatics (Oxford, England) · 2016Article
- A physiome interoperability roadmap for personalized drug development.Interface focus · 2016Article
- Bringing Model-Based Prediction to Oncology Clinical Practice: A Review of Pharmacometrics Principles and Applications.The oncologist · 2016Review
- The European Bioinformatics Institute in 2016: Data growth and integration.Nucleic acids research · 2016Article
- The promises of quantitative systems pharmacology modelling for drug development.Computational and structural biotechnology journal · 2016Review
- Effect of Kidney Function on Drug Kinetics and Dosing in Neonates, Infants, and Children.Clinical pharmacokinetics · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Model-based drug development (MBDD) is accepted as a vital approach in understanding patients' drug-related benefit and risk by integrating quantitative information integration from diverse sources collected throughout drug development.(1) This perspective introduces the activities of the Drug and Disease Model Resources (DDMoRe) consortium, founded in 2011 through the Innovative Medicines Initiative Joint Undertaking (IMI-JU)(2) as a European public-private partnership to address a lack of common tools, languages, and standards for modeling and simulation (M&S) to improve model-based knowledge integration.CPT: Pharmacometrics & Systems Pharmacology (2013) 2, e34; doi:10.1038/psp.2013.10; advance online publication 20 March 2013.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.